2024 Non-Alcoholic Steatohepatitis Biomarkers Market Report : Market Size, Growth Drivers, And Key Trends | Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics

"The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The non-alcoholic steatohepatitis biomarkers market size has grown exponentially in recent years. It will grow from $1.11 billion in 2023 to $1.39 billion in 2024 at a compound annual growth rate (CAGR) of 25.6%. The growth in the historic period can be attributed to diabetes and metabolic syndrom, awareness and screening programs, liver biopsy limitations, regulatory support, shift towards personalized medicine, clinical trials in nash..

The non-alcoholic steatohepatitis biomarkers market size is expected to see exponential growth in the next few years. It will grow to $3.2 billion in 2028 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to emergence of novel therapies, expansion of precision medicine approaches, patient advocacy initiatives, integration of multi-omics data, enhanced patient engagement.. Major trends in the forecast period include telemedicine and remote monitoring, innovative diagnostic platforms, global collaborations in research, technological advancements in biomarker discovery, integration of artificial intelligence (ai), inclusion of imaging biomarkers..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp

Market Segmentation:
The non-alcoholic steatohepatitis biomarkers market covered in this report is segmented -

1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
3) By End Use: Research Institutes And Academics, Diagnostic Centres, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses

Major Driver - Rising Liver Cancer Prevalence Fuels Expansion Of Non-Alcoholic Steatohepatitis Biomarkers Market
The growing prevalence of liver cancer is expected to propel the growth of the non-alcoholic steatohepatitis biomarkers market going forward. Liver cancer refers to the development of malignant tumors within the liver and can start in the liver itself (primary liver cancer) or spread to the liver from other parts of the body (secondary or metastatic liver cancer). Non-alcoholic steatohepatitis (NASH) biomarkers are used in liver cancer for early detection, disease progression monitoring, and treatment response assessment, to provide prognostic information, and can help reduce the need for invasive procedures. For instance, in October 2022, according to the Journal of Hepatology, a Switzerland-based medical journal that primarily focuses on hepatology, according to recent studies, hepatitis B virus (HBV) is thought to be responsible for about 56% of liver cancer cases. Therefore, the growing prevalence of liver cancer is driving the growth of the non-alcoholic steatohepatitis biomarkers market.

Competitive Landscape:
Major companies operating in the non-alcoholic steatohepatitis biomarkers market report are Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Xeptagen SpA, Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Conatus Pharmaceuticals, Immuron Ltd, Metacrine .

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

Top Trend - Advancements In Nis4 Technology Pave The Way For Innovative Blood-Based Molecular Diagnostic Test
Technological advancements are a key trend in gaining popularity in the non-alcoholic steatohepatitis biomarkers market. Major companies operating in the non-alcoholic steatohepatitis biomarkers market are focused on developing innovative solutions to strengthen their position in the market. For instance, in October 2022, GENFIT, a France-based late-stage biopharmaceutical company, and LabCorp, a US-based life sciences company, agreed on a five-year exclusive licensing deal for GENFIT's NIS4 technology to aid in identifying patients with non-alcoholic-steatohepatitis-at-risk (NASH). NIS4 technology is an innovative, multi-biomarker-based algorithm specifically developed to identify patients with non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis (F > 2), also referred to as at-risk NASH. As part of the agreement, LabCorp will develop and commercialize a blood-based molecular diagnostic test utilizing NIS4 technology in the United States and Canada, giving widespread access to healthcare professionals.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Non-Alcoholic Steatohepatitis Biomarkers Market Characteristics
3. Non-Alcoholic Steatohepatitis Biomarkers Market Trends And Strategies
4. Non-Alcoholic Steatohepatitis Biomarkers Market - Macro Economic Scenario
5. Non-Alcoholic Steatohepatitis Biomarkers Market Size And Growth
…..
27. Non-Alcoholic Steatohepatitis Biomarkers Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.